{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:33:55Z","timestamp":1794576835070,"version":"4.9.1"},"reference-count":101,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100007684","name":"Ministry of Education and Science of Ukraine","doi-asserted-by":"crossref","award":["0125U000396"],"award-info":[{"award-number":["0125U000396"]}],"id":[{"id":"10.13039\/501100007684","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Chronic Stress"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>Chronic stress and traumatic events affect the psychological and physiological state of a person. Post-traumatic stress disorder (PTSD) is a type of psychological stress that occurs in critical situations that pose a direct threat to the life of the person and\/or his or her loved ones. The prevalence of PTSD is increasing every year due to growing exposure to traumatic factors such as wars, natural disasters, and other crises. These events lead to severe psychological consequences, affecting a rising number of people worldwide. Currently, PTSD can be challenging to treat due to the complex nature of the disorder, variability in individual responses to treatment, and limitations in available therapeutic options. Considering the emergency need for effective PTSD treatment, a drug repurposing strategy presents a promising avenue to accelerate the availability of therapies. Here, we summarized and described drugs that were repurposed for alleviating PTSD symptoms. Moreover, we discussed the potential of some drugs, including alpha-adrenergic modulators, cannabinoids, glutamatergic modulators, and antipsychotics, for being repurposed for PTSD treatment. Drug repurposing implies the rapid identification of compounds with an established safety profile and known therapeutic effects that may be effective in PTSD. Repurposing existing drugs with already established pharmacokinetics and pharmacodynamics may shorten development timelines, facilitate a direct transition to the second phase of clinical trials, and lower costs. However, potential drawbacks and negative aspects should be discussed comprehensively.<\/jats:p>","DOI":"10.1177\/24705470251392481","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T17:40:37Z","timestamp":1761327637000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Repurposing Existing Drugs for the Treatment of Post-Traumatic Stress Disorder"],"prefix":"10.1177","volume":"9","author":[{"given":"Olha","family":"Strilbytska","sequence":"first","affiliation":[{"name":"Vasyl Stefanyk Carpathian National University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4627-1987","authenticated-orcid":false,"given":"Oleh","family":"Lushchak","sequence":"additional","affiliation":[{"name":"Vasyl Stefanyk Carpathian National University"},{"name":"Research and Development University, 13a Rustaveli Str., Ivano-Frankivsk, 76018, Ukraine"},{"name":"Kyiv School of Economics, 3 Shpaka Str, Kyiv, 02000, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1515\/mr-2022-0012"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1037\/tra0001281"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/bs7010007"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291717000708"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/20008198.2017.1353383"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2011.13.2\/jsherin"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30934-1"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100773"},{"key":"e_1_3_3_10_2","first-page":"928","article-title":"Metabolic and immune dysfunctions in post-traumatic stress disorder: What can we learn from animal models?","volume":"22","author":"Lushchak O","year":"2023","unstructured":"Lushchak O, Orru M, Strilbytska O, et al. Metabolic and immune dysfunctions in post-traumatic stress disorder: What can we learn from animal models? EXCLI J. 2023;22:928-945.","journal-title":"EXCLI J"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1222826"},{"issue":"2","key":"e_1_3_3_12_2","article-title":"An exploratory study of physiological and biochemical parameters to identify simple, robust and relevant biomarkers for therapeutic interventions for ptsd: study rationale, key elements of design and a context of war in Ukraine","volume":"69","author":"Serhiyenko V","year":"2022","unstructured":"Serhiyenko V, Holzmann K, Holota S, et al. An exploratory study of physiological and biochemical parameters to identify simple, robust and relevant biomarkers for therapeutic interventions for ptsd: study rationale, key elements of design and a context of war in Ukraine. Proc Shevchenko Sci Soc Med Sci [Internet]. 2022;69(2).","journal-title":"Proc Shevchenko Sci Soc Med Sci [Internet]"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-824315-2.01123-4"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.05.026"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/med.21773"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23328-0"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.2011619"},{"key":"e_1_3_3_19_2","first-page":"265","volume-title":"Goodman & Gilman\u2019s the Pharmacological Basis of Therapeutics: Section III Chapter 12 Neurotransmission and the Central Nervous System. 11th","author":"Hardman JG","year":"2008","unstructured":"Hardman JG, Limbird LE, Molinoff PB. Goodman & Gilman\u2019s the Pharmacological Basis of Therapeutics: Section III Chapter 12 Neurotransmission and the Central Nervous System. 11th. McGraw-Hill; 2008:265-578."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2094"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20481"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1166"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1039\/C5MB00306G"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.24612"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.657714"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X12666140619204251"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12497"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.159.1.123"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00714.x"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0112"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.07.011"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291717000885"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900014504"},{"issue":"3","key":"e_1_3_3_34_2","first-page":"71","article-title":"Valproate in bipolar disorder: Case examples from a family practice","volume":"1","author":"Manning JS","year":"1999","unstructured":"Manning JS. Valproate in bipolar disorder: Case examples from a family practice. Prim Care Companion J Clin Psychiatry. 1999;1(3):71-73.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300203"},{"issue":"3","key":"e_1_3_3_36_2","article-title":"Azapirones for generalised anxiety disorder","volume":"2006","author":"Chessick CA","year":"2006","unstructured":"Chessick CA, Allen MH, Thase M, et al. Azapirones for generalised anxiety disorder. Cochrane Database Syst Rev. 2006;2006(3):CD006115.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.02.001"},{"issue":"1","key":"e_1_3_3_38_2","first-page":"13","article-title":"Neurobiology of post-traumatic stress disorder","volume":"14","author":"Heim C","year":"2009","unstructured":"Heim C, Nemeroff CB. Neurobiology of post-traumatic stress disorder. CNS Spectr. 2009;14(1 Suppl 1):13-24.","journal-title":"CNS Spectr"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-010-9606-9"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1080\/10253890.2020.1803824"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-64123-6.00004-7"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/10253890802046281"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2016.00072"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-021-00728-1"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2020.07.006"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-00923-1"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb00291.x"},{"issue":"4","key":"e_1_3_3_48_2","first-page":"242","article-title":"Neurotransmitter alterations in PTSD: Catecholamines and serotonin","volume":"4","author":"Southwick SM","year":"1999","unstructured":"Southwick SM, Paige S, Morgan 3rd CA, et al. Neurotransmitter alterations in PTSD: Catecholamines and serotonin. Semin Clin Neuropsychiatry. 1999;4(4):242-248.","journal-title":"Semin Clin Neuropsychiatry"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.559401"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2016.11.064"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.640977"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S159855"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00210-8"},{"issue":"1","key":"e_1_3_3_54_2","first-page":"32","article-title":"Pharmacotherapy for post-traumatic stress disorder in combat veterans: Focus on antidepressants and atypical antipsychotic agents","volume":"37","author":"Alexander W","year":"2012","unstructured":"Alexander W. Pharmacotherapy for post-traumatic stress disorder in combat veterans: Focus on antidepressants and atypical antipsychotic agents. P T. 2012;37(1):32-38.","journal-title":"P T"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00221-3"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1039\/C5CP05771J"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnsyn.2023.1124112"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-04818-5"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2021.03.008"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5120117"},{"issue":"8","key":"e_1_3_3_61_2","first-page":"1731","article-title":"Novel pharmacological targets of post-traumatic stress disorders","volume":"13","author":"Marazziti D","year":"2023","unstructured":"Marazziti D, Carmassi C, Cappellato G, et al. Novel pharmacological targets of post-traumatic stress disorders. Life (Basel). 2023;13(8):1731.","journal-title":"Life (Basel)"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.2344\/0003-3006-62.1.31"},{"issue":"1","key":"e_1_3_3_63_2","first-page":"67","article-title":"An open-label study of doxazosin extended-release for PTSD: Findings and recommendations for future research on doxazosin","volume":"16","author":"Richards A","year":"2018","unstructured":"Richards A, Inslicht S, Ruoff LM, et al. An open-label study of doxazosin extended-release for PTSD: Findings and recommendations for future research on doxazosin. Focus (Am Psychiatr Publ). 2018;16(1):67-73.","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2018.08.009"},{"issue":"5","key":"e_1_3_3_65_2","article-title":"Doxazosin for the treatment of nightmares: Does it really work? A case report","volume":"14","author":"Sethi R","year":"2012","unstructured":"Sethi R, Vasudeva S. Doxazosin for the treatment of nightmares: Does it really work? A case report. Prim Care Companion CNS Disord. 2012;14(5):PCC.12l01356.","journal-title":"Prim Care Companion CNS Disord"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09681"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181c827ae"},{"issue":"1","key":"e_1_3_3_68_2","first-page":"26","article-title":"Doxazosin, an \u03b1-1-adrenergic-receptor antagonist, for nightmares in patients with post-traumatic stress disorder and\/or borderline personality disorder: A chart review","volume":"50","author":"Roepke S","year":"2017","unstructured":"Roepke S, Danker-Hopfe H, Repantis D, et al. Doxazosin, an \u03b1-1-adrenergic-receptor antagonist, for nightmares in patients with post-traumatic stress disorder and\/or borderline personality disorder: A chart review. Pharmacopsychiatry. 2017;50(1):26-31.","journal-title":"Pharmacopsychiatry"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2022.03.045"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI109677"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2010.00227.x"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2015.04.006"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1177\/0891988703256050"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0208"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1159\/000362243"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200202000-00013"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.4103\/IJPSYM.IJPSYM_228_19"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1547-16.2016"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.11.006"},{"issue":"3","key":"e_1_3_3_80_2","first-page":"296","article-title":"A randomised controlled trial of repeated ketamine administration for chronic post-traumatic stress disorder","volume":"21","author":"Feder A","year":"2023","unstructured":"Feder A, Costi S, Rutter SB, et al. A randomised controlled trial of repeated ketamine administration for chronic post-traumatic stress disorder. Focus (Am Psychiatr Publ). 2023;21(3):296-305.","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.64719\/pb.4561"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200304000-00012"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.07.005"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C040"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200302000-00003"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674370304800416"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00011-6"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076050"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200202000-00021"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000106234.36344.a4"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.12.1982"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2008.3002"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.14.1837"},{"issue":"4","key":"e_1_3_3_94_2","first-page":"321","article-title":"Adjunctive minocycline for treatment of post-traumatic stress disorder","volume":"120","author":"Gerst A","year":"2021","unstructured":"Gerst A, Murthy T, Elson A, et al. Adjunctive minocycline for treatment of post-traumatic stress disorder. WMJ. 2021;120(4):321-324.","journal-title":"WMJ"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2003.09.014"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852913000096"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2024.114855"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.3390\/v16121938"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112230"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-017-0953-6"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.2337\/db20-174-LB"},{"issue":"7","key":"e_1_3_3_102_2","first-page":"22","article-title":"Comorbidity of psychiatric disorders and post-traumatic stress disorder","volume":"61","author":"Brady KT","year":"2000","unstructured":"Brady KT, Killeen TK, Brewerton T, Lucerini S. Comorbidity of psychiatric disorders and post-traumatic stress disorder. J Clin Psychiatry. 2000;61(Suppl 7):22-32.","journal-title":"J Clin Psychiatry"}],"container-title":["Chronic Stress"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24705470251392481","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24705470251392481","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24705470251392481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:13:35Z","timestamp":1761592415000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24705470251392481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":101,"alternative-id":["10.1177\/24705470251392481"],"URL":"https:\/\/doi.org\/10.1177\/24705470251392481","relation":{},"ISSN":["2470-5470","2470-5470"],"issn-type":[{"value":"2470-5470","type":"print"},{"value":"2470-5470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"24705470251392481"}}